The European Commission has approved lecanemab, the first Alzheimer’s treatment targeting the disease’s underlying processes, marking a historic milestone in EU healthcare. Intended for patients in the early stages of Alzheimer's, lecanemab represents a shift from conventional therapies focused on symptomatic relief. The approval follows a change in stance by the European Medicines Agency, which had previously hesitated. Despite its approval, experts caution that the drug’s accessibility is limited, as only a small percentage of Alzheimer’s patients meet the criteria for treatment. Lecanemab is already authorized in the US, UK, and Japan.
The European Commission has approved lecanemab, the first therapy targeting the underlying processes of Alzheimer's, marking a significant advancement in the treatment landscape.
Lecanemab, sold under the brand name Leqembi, is now authorized in the EU, following a prior recommendation by the European Medicines Agency.
Collection
[
|
...
]